excel: 25397

excel with dem: 20383

remove no baseline cre: 18319

remove missing esrd_kt!=0, eGFR_CRE_baseline <10 : 18157

remove missing last_cre_date< ICI_date:17937 (17752 with labs after ici date)

remove 216 placebo :17721

remove 3 death_date < ici_date(RPDR error): 17718

all

Characteristic N = 2,6531
age_ici 70 (63, 77)
male
    0 999 (38%)
    1 1,654 (62%)
Race
    Asian 106 (4.0%)
    Black 165 (6.2%)
    Other/Unknown 152 (5.7%)
    White 2,230 (84%)
Ethnic_Group
    Hispanic 98 (3.7%)
    Non_hispanic 2,386 (90%)
    Other 169 (6.4%)
ckd_progression
    0 2,540 (98%)
    1 56 (2.2%)
    Missing 57
ckd_incidence
    0 2,442 (94%)
    1 154 (5.9%)
    Missing 57
eskd_composite
    0 2,615 (99%)
    1 38 (1.4%)
ckd_composite
    0 2,420 (91%)
    1 233 (8.8%)
ckd_stage_baseline
    1 947 (36%)
    2 1,056 (40%)
    3 584 (22%)
    4 61 (2.3%)
    5 5 (0.2%)
aki
    0 1,651 (62%)
    1 1,002 (38%)
dm
    1 2,653 (100%)
htn
    0 280 (11%)
    1 2,373 (89%)
cad
    0 1,455 (55%)
    1 1,198 (45%)
cirrhosis
    0 2,506 (94%)
    1 147 (5.5%)
ace_arb
    0 749 (28%)
    1 1,904 (72%)
diu
    0 765 (29%)
    1 1,888 (71%)
ppi
    0 514 (19%)
    1 2,139 (81%)
steroids
    0 394 (15%)
    1 2,259 (85%)
smoking
    0 1,002 (38%)
    1 1,651 (62%)
Bevacizumab
    0 2,468 (93%)
    1 185 (7.0%)
Cisplatin
    0 2,298 (87%)
    1 355 (13%)
Carboplatin
    0 1,749 (66%)
    1 904 (34%)
Pemetrexed
    0 2,301 (87%)
    1 352 (13%)
Gemcitabine
    0 2,309 (87%)
    1 344 (13%)
Cetuximab
    0 2,579 (97%)
    1 74 (2.8%)
Trastuzumab
    0 2,596 (98%)
    1 57 (2.1%)
VEGF_TKI
    0 2,395 (90%)
    1 258 (9.7%)
statins
    0 576 (22%)
    1 2,077 (78%)
ICI_Class
    PD1 1,811 (68%)
    Combination 292 (11%)
    CTLA4 100 (3.8%)
    PDL1 450 (17%)
nephrotoxic_chemo
    0 1,255 (47%)
    1 1,398 (53%)
pre_CRE_180days 0.94 (0.74, 1.17)
pre_HGB_180days 11.70 (10.30, 13.10)
    Missing 6
pre_ALB_180days 3.90 (3.50, 4.20)
    Missing 15
eGFR_CRE_baseline 80 (61, 95)
1 Median (Q1, Q3); n (%)

1year

Characteristic N = 1,2611
age_ici 70 (62, 76)
male
    0 482 (38%)
    1 779 (62%)
Race
    Asian 50 (4.0%)
    Black 80 (6.3%)
    Other/Unknown 68 (5.4%)
    White 1,063 (84%)
Ethnic_Group
    Hispanic 45 (3.6%)
    Non_hispanic 1,144 (91%)
    Other 72 (5.7%)
ckd_incidence_1year
    0 1,202 (95%)
    1 59 (4.7%)
ckd_progression_1year
    0 1,244 (99%)
    1 17 (1.3%)
eskd_composite_1year
    0 1,253 (99%)
    1 8 (0.6%)
ckd_composite_1year
    0 1,181 (94%)
    1 80 (6.3%)
ckd_stage_1year
    1 393 (31%)
    2 504 (40%)
    3 329 (26%)
    4 32 (2.5%)
    5 3 (0.2%)
ckd_stage_baseline
    1 433 (34%)
    2 516 (41%)
    3 291 (23%)
    4 20 (1.6%)
    5 1 (<0.1%)
aki
    0 715 (57%)
    1 546 (43%)
dm
    1 1,261 (100%)
htn
    0 139 (11%)
    1 1,122 (89%)
cad
    0 731 (58%)
    1 530 (42%)
cirrhosis
    0 1,207 (96%)
    1 54 (4.3%)
ace_arb
    0 304 (24%)
    1 957 (76%)
diu
    0 352 (28%)
    1 909 (72%)
ppi
    0 239 (19%)
    1 1,022 (81%)
steroids
    0 194 (15%)
    1 1,067 (85%)
smoking
    0 482 (38%)
    1 779 (62%)
statins
    0 234 (19%)
    1 1,027 (81%)
ICI_Class
    PD1 832 (66%)
    Combination 157 (12%)
    CTLA4 44 (3.5%)
    PDL1 228 (18%)
nephrotoxic_chemo
    0 604 (48%)
    1 657 (52%)
pre_CRE_180days 0.95 (0.75, 1.17)
pre_HGB_180days 12.20 (10.90, 13.40)
    Missing 5
pre_ALB_180days 4.10 (3.80, 4.30)
    Missing 9
eGFR_CRE_baseline 79 (61, 95)
1 Median (Q1, Q3); n (%)

2year

Characteristic N = 7631
age_ici 69 (61, 75)
male
    0 295 (39%)
    1 468 (61%)
Race
    Asian 25 (3.3%)
    Black 47 (6.2%)
    Other/Unknown 39 (5.1%)
    White 652 (85%)
Ethnic_Group
    Hispanic 26 (3.4%)
    Non_hispanic 694 (91%)
    Other 43 (5.6%)
ckd_incidence_2year
    0 693 (91%)
    1 70 (9.2%)
ckd_progression_2year
    0 740 (97%)
    1 23 (3.0%)
eskd_composite_2year
    0 752 (99%)
    1 11 (1.4%)
ckd_composite_2year
    0 665 (87%)
    1 98 (13%)
ckd_stage_1year
    1 235 (31%)
    2 309 (40%)
    3 199 (26%)
    4 18 (2.4%)
    5 2 (0.3%)
ckd_stage_2year
    1 220 (29%)
    2 319 (42%)
    3 195 (26%)
    4 25 (3.3%)
    5 4 (0.5%)
ckd_stage_baseline
    1 262 (34%)
    2 315 (41%)
    3 171 (22%)
    4 14 (1.8%)
    5 1 (0.1%)
aki
    0 423 (55%)
    1 340 (45%)
dm
    1 763 (100%)
htn
    0 80 (10%)
    1 683 (90%)
cad
    0 463 (61%)
    1 300 (39%)
cirrhosis
    0 735 (96%)
    1 28 (3.7%)
ace_arb
    0 181 (24%)
    1 582 (76%)
diu
    0 213 (28%)
    1 550 (72%)
ppi
    0 143 (19%)
    1 620 (81%)
steroids
    0 118 (15%)
    1 645 (85%)
smoking
    0 292 (38%)
    1 471 (62%)
statins
    0 142 (19%)
    1 621 (81%)
ICI_Class
    PD1 510 (67%)
    Combination 90 (12%)
    CTLA4 32 (4.2%)
    PDL1 131 (17%)
nephrotoxic_chemo
    0 387 (51%)
    1 376 (49%)
pre_CRE_180days 0.95 (0.76, 1.17)
pre_HGB_180days 12.40 (11.00, 13.60)
    Missing 4
pre_ALB_180days 4.10 (3.80, 4.30)
    Missing 5
eGFR_CRE_baseline 80 (61, 94)
1 Median (Q1, Q3); n (%)

3year

Characteristic N = 4461
age_ici 68 (61, 75)
male
    0 175 (39%)
    1 271 (61%)
Race
    Asian 16 (3.6%)
    Black 24 (5.4%)
    Other/Unknown 24 (5.4%)
    White 382 (86%)
Ethnic_Group
    Hispanic 15 (3.4%)
    Non_hispanic 406 (91%)
    Other 25 (5.6%)
ckd_incidence_3year
    0 387 (87%)
    1 59 (13%)
ckd_progression_3year
    0 427 (96%)
    1 19 (4.3%)
eskd_composite_3year
    0 440 (99%)
    1 6 (1.3%)
ckd_composite_3year
    0 365 (82%)
    1 81 (18%)
ckd_stage_1year
    1 142 (32%)
    2 175 (39%)
    3 118 (26%)
    4 10 (2.2%)
    5 1 (0.2%)
ckd_stage_2year
    1 134 (30%)
    2 187 (42%)
    3 114 (26%)
    4 11 (2.5%)
    5 0 (0%)
ckd_stage_3year
    1 126 (28%)
    2 182 (41%)
    3 124 (28%)
    4 12 (2.7%)
    5 2 (0.4%)
ckd_stage_baseline
    1 165 (37%)
    2 176 (39%)
    3 99 (22%)
    4 6 (1.3%)
    5 0 (0%)
aki
    0 252 (57%)
    1 194 (43%)
dm
    1 446 (100%)
htn
    0 52 (12%)
    1 394 (88%)
cad
    0 272 (61%)
    1 174 (39%)
cirrhosis
    0 430 (96%)
    1 16 (3.6%)
ace_arb
    0 98 (22%)
    1 348 (78%)
diu
    0 129 (29%)
    1 317 (71%)
ppi
    0 84 (19%)
    1 362 (81%)
steroids
    0 69 (15%)
    1 377 (85%)
smoking
    0 168 (38%)
    1 278 (62%)
statins
    0 75 (17%)
    1 371 (83%)
ICI_Class
    PD1 304 (68%)
    Combination 51 (11%)
    CTLA4 23 (5.2%)
    PDL1 68 (15%)
nephrotoxic_chemo
    0 246 (55%)
    1 200 (45%)
pre_CRE_180days 0.94 (0.76, 1.17)
pre_HGB_180days 12.60 (11.10, 13.70)
    Missing 3
pre_ALB_180days 4.10 (3.80, 4.30)
    Missing 3
eGFR_CRE_baseline 80 (62, 96)
1 Median (Q1, Q3); n (%)

4year

Characteristic N = 2811
age_ici 68 (60, 74)
male
    0 110 (39%)
    1 171 (61%)
Race
    Asian 7 (2.5%)
    Black 11 (3.9%)
    Other/Unknown 17 (6.0%)
    White 246 (88%)
Ethnic_Group
    Hispanic 11 (3.9%)
    Non_hispanic 251 (89%)
    Other 19 (6.8%)
ckd_incidence_4year
    0 238 (85%)
    1 43 (15%)
ckd_progression_4year
    0 263 (94%)
    1 18 (6.4%)
eskd_composite_4year
    0 276 (98%)
    1 5 (1.8%)
ckd_composite_4year
    0 218 (78%)
    1 63 (22%)
ckd_stage_1year
    1 86 (31%)
    2 112 (40%)
    3 73 (26%)
    4 9 (3.2%)
    5 1 (0.4%)
ckd_stage_2year
    1 81 (29%)
    2 120 (43%)
    3 71 (25%)
    4 9 (3.2%)
    5 0 (0%)
ckd_stage_3year
    1 73 (26%)
    2 119 (42%)
    3 82 (29%)
    4 6 (2.1%)
    5 1 (0.4%)
ckd_stage_4year
    1 78 (28%)
    2 115 (41%)
    3 82 (29%)
    4 5 (1.8%)
    5 1 (0.4%)
ckd_stage_baseline
    1 96 (34%)
    2 116 (41%)
    3 65 (23%)
    4 4 (1.4%)
    5 0 (0%)
aki
    0 152 (54%)
    1 129 (46%)
dm
    1 281 (100%)
htn
    0 32 (11%)
    1 249 (89%)
cad
    0 167 (59%)
    1 114 (41%)
cirrhosis
    0 268 (95%)
    1 13 (4.6%)
ace_arb
    0 51 (18%)
    1 230 (82%)
diu
    0 72 (26%)
    1 209 (74%)
ppi
    0 56 (20%)
    1 225 (80%)
steroids
    0 49 (17%)
    1 232 (83%)
smoking
    0 105 (37%)
    1 176 (63%)
statins
    0 40 (14%)
    1 241 (86%)
ICI_Class
    PD1 194 (69%)
    Combination 32 (11%)
    CTLA4 12 (4.3%)
    PDL1 43 (15%)
nephrotoxic_chemo
    0 166 (59%)
    1 115 (41%)
pre_CRE_180days 0.96 (0.78, 1.19)
pre_HGB_180days 12.60 (11.10, 13.90)
    Missing 1
pre_ALB_180days 4.10 (3.80, 4.40)
    Missing 1
eGFR_CRE_baseline 79 (61, 95)
1 Median (Q1, Q3); n (%)

5year

Characteristic N = 1771
age_ici 67 (59, 74)
male
    0 70 (40%)
    1 107 (60%)
Race
    Asian 3 (1.7%)
    Black 10 (5.6%)
    Other/Unknown 13 (7.3%)
    White 151 (85%)
Ethnic_Group
    Hispanic 8 (4.5%)
    Non_hispanic 155 (88%)
    Other 14 (7.9%)
ckd_incidence_5year
    0 148 (84%)
    1 29 (16%)
ckd_progression_5year
    0 160 (90%)
    1 17 (9.6%)
eskd_composite_5year
    0 174 (98%)
    1 3 (1.7%)
ckd_composite_5year
    0 129 (73%)
    1 48 (27%)
ckd_stage_1year
    1 53 (30%)
    2 75 (42%)
    3 45 (25%)
    4 4 (2.3%)
    5 0 (0%)
ckd_stage_2year
    1 50 (28%)
    2 81 (46%)
    3 42 (24%)
    4 4 (2.3%)
    5 0 (0%)
ckd_stage_3year
    1 46 (26%)
    2 84 (47%)
    3 45 (25%)
    4 1 (0.6%)
    5 1 (0.6%)
ckd_stage_4year
    1 50 (28%)
    2 78 (44%)
    3 47 (27%)
    4 1 (0.6%)
    5 1 (0.6%)
ckd_stage_5year
    1 44 (25%)
    2 87 (49%)
    3 40 (23%)
    4 5 (2.8%)
    5 1 (0.6%)
ckd_stage_baseline
    1 60 (34%)
    2 76 (43%)
    3 38 (21%)
    4 3 (1.7%)
    5 0 (0%)
aki
    0 104 (59%)
    1 73 (41%)
dm
    1 177 (100%)
htn
    0 20 (11%)
    1 157 (89%)
cad
    0 109 (62%)
    1 68 (38%)
cirrhosis
    0 172 (97%)
    1 5 (2.8%)
ace_arb
    0 35 (20%)
    1 142 (80%)
diu
    0 43 (24%)
    1 134 (76%)
ppi
    0 35 (20%)
    1 142 (80%)
steroids
    0 34 (19%)
    1 143 (81%)
smoking
    0 68 (38%)
    1 109 (62%)
statins
    0 23 (13%)
    1 154 (87%)
ICI_Class
    PD1 124 (70%)
    Combination 14 (7.9%)
    CTLA4 9 (5.1%)
    PDL1 30 (17%)
nephrotoxic_chemo
    0 108 (61%)
    1 69 (39%)
pre_CRE_180days 0.95 (0.75, 1.16)
pre_HGB_180days 12.60 (11.15, 13.85)
    Missing 1
pre_ALB_180days 4.10 (3.80, 4.30)
    Missing 1
eGFR_CRE_baseline 79 (61, 96)
1 Median (Q1, Q3); n (%)

6year

Characteristic N = 1141
age_ici 65 (59, 74)
male
    0 47 (41%)
    1 67 (59%)
Race
    Asian 2 (1.8%)
    Black 9 (7.9%)
    Other/Unknown 10 (8.8%)
    White 93 (82%)
Ethnic_Group
    Hispanic 5 (4.4%)
    Non_hispanic 98 (86%)
    Other 11 (9.6%)
ckd_incidence_6year
    0 93 (82%)
    1 21 (18%)
ckd_progression_6year
    0 103 (90%)
    1 11 (9.6%)
eskd_composite_6year
    0 112 (98%)
    1 2 (1.8%)
ckd_composite_6year 34 (30%)
ckd_stage_1year
    1 38 (33%)
    2 49 (43%)
    3 26 (23%)
    4 1 (0.9%)
    5 0 (0%)
ckd_stage_2year
    1 35 (31%)
    2 53 (46%)
    3 26 (23%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_3year
    1 35 (31%)
    2 50 (44%)
    3 28 (25%)
    4 1 (0.9%)
    5 0 (0%)
ckd_stage_4year
    1 36 (32%)
    2 49 (43%)
    3 29 (25%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_5year
    1 31 (27%)
    2 56 (49%)
    3 25 (22%)
    4 2 (1.8%)
    5 0 (0%)
ckd_stage_6year
    1 30 (26%)
    2 56 (49%)
    3 22 (19%)
    4 6 (5.3%)
    5 0 (0%)
ckd_stage_baseline
    1 43 (38%)
    2 46 (40%)
    3 24 (21%)
    4 1 (0.9%)
    5 0 (0%)
aki
    0 67 (59%)
    1 47 (41%)
dm
    1 114 (100%)
htn
    0 14 (12%)
    1 100 (88%)
cad
    0 75 (66%)
    1 39 (34%)
cirrhosis
    0 112 (98%)
    1 2 (1.8%)
ace_arb
    0 24 (21%)
    1 90 (79%)
diu
    0 30 (26%)
    1 84 (74%)
ppi
    0 23 (20%)
    1 91 (80%)
steroids
    0 22 (19%)
    1 92 (81%)
smoking
    0 48 (42%)
    1 66 (58%)
statins
    0 13 (11%)
    1 101 (89%)
ICI_Class
    PD1 75 (66%)
    Combination 8 (7.0%)
    CTLA4 8 (7.0%)
    PDL1 23 (20%)
nephrotoxic_chemo
    0 73 (64%)
    1 41 (36%)
pre_CRE_180days 0.93 (0.72, 1.12)
pre_HGB_180days 12.60 (11.10, 13.90)
pre_ALB_180days 4.10 (3.80, 4.30)
eGFR_CRE_baseline 82 (66, 98)
1 Median (Q1, Q3); n (%)

7year

Characteristic N = 761
age_ici 64 (58, 73)
male
    0 28 (37%)
    1 48 (63%)
Race
    Asian 1 (1.3%)
    Black 6 (7.9%)
    Other/Unknown 7 (9.2%)
    White 62 (82%)
Ethnic_Group
    Hispanic 4 (5.3%)
    Non_hispanic 64 (84%)
    Other 8 (11%)
ckd_incidence_7year
    0 56 (74%)
    1 20 (26%)
ckd_progression_7year
    0 72 (95%)
    1 4 (5.3%)
eskd_composite_7year
    0 75 (99%)
    1 1 (1.3%)
ckd_composite_7year 25 (33%)
ckd_stage_1year
    1 28 (37%)
    2 32 (42%)
    3 15 (20%)
    4 1 (1.3%)
    5 0 (0%)
ckd_stage_2year
    1 25 (33%)
    2 34 (45%)
    3 17 (22%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_3year
    1 24 (32%)
    2 35 (46%)
    3 17 (22%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_4year
    1 25 (33%)
    2 31 (41%)
    3 20 (26%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_5year
    1 20 (26%)
    2 39 (51%)
    3 16 (21%)
    4 1 (1.3%)
    5 0 (0%)
ckd_stage_6year
    1 20 (26%)
    2 37 (49%)
    3 15 (20%)
    4 4 (5.3%)
    5 0 (0%)
ckd_stage_7year
    1 20 (26%)
    2 33 (43%)
    3 19 (25%)
    4 3 (3.9%)
    5 1 (1.3%)
ckd_stage_baseline
    1 30 (39%)
    2 30 (39%)
    3 15 (20%)
    4 1 (1.3%)
    5 0 (0%)
aki
    0 47 (62%)
    1 29 (38%)
dm
    1 76 (100%)
htn
    0 10 (13%)
    1 66 (87%)
cad
    0 53 (70%)
    1 23 (30%)
cirrhosis
    0 74 (97%)
    1 2 (2.6%)
ace_arb
    0 15 (20%)
    1 61 (80%)
diu
    0 24 (32%)
    1 52 (68%)
ppi
    0 15 (20%)
    1 61 (80%)
steroids
    0 14 (18%)
    1 62 (82%)
smoking
    0 29 (38%)
    1 47 (62%)
statins
    0 5 (6.6%)
    1 71 (93%)
ICI_Class
    PD1 53 (70%)
    Combination 4 (5.3%)
    CTLA4 6 (7.9%)
    PDL1 13 (17%)
nephrotoxic_chemo
    0 50 (66%)
    1 26 (34%)
pre_CRE_180days 0.95 (0.76, 1.11)
pre_HGB_180days 12.60 (11.00, 13.90)
pre_ALB_180days 4.10 (3.90, 4.30)
eGFR_CRE_baseline 82 (69, 98)
1 Median (Q1, Q3); n (%)

8year

Characteristic N = 401
age_ici 67 (58, 73)
male
    0 12 (30%)
    1 28 (70%)
Race
    Asian 0 (0%)
    Black 3 (7.5%)
    Other/Unknown 2 (5.0%)
    White 35 (88%)
Ethnic_Group
    Hispanic 1 (2.5%)
    Non_hispanic 34 (85%)
    Other 5 (13%)
ckd_incidence_8year
    0 26 (65%)
    1 14 (35%)
ckd_progression_8year
    0 36 (90%)
    1 4 (10%)
eskd_composite_8year
    0 40 (100%)
    1 0 (0%)
ckd_composite_8year 18 (45%)
ckd_stage_1year
    1 13 (33%)
    2 18 (45%)
    3 9 (23%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_2year
    1 9 (23%)
    2 21 (53%)
    3 10 (25%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_3year
    1 11 (28%)
    2 19 (48%)
    3 10 (25%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_4year
    1 13 (33%)
    2 14 (35%)
    3 13 (33%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_5year
    1 9 (23%)
    2 19 (48%)
    3 12 (30%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_6year
    1 8 (20%)
    2 20 (50%)
    3 11 (28%)
    4 1 (2.5%)
    5 0 (0%)
ckd_stage_7year
    1 9 (23%)
    2 14 (35%)
    3 15 (38%)
    4 2 (5.0%)
    5 0 (0%)
ckd_stage_8year
    1 8 (20%)
    2 14 (35%)
    3 16 (40%)
    4 2 (5.0%)
    5 0 (0%)
ckd_stage_baseline
    1 12 (30%)
    2 17 (43%)
    3 11 (28%)
    4 0 (0%)
    5 0 (0%)
aki
    0 22 (55%)
    1 18 (45%)
dm
    1 40 (100%)
htn
    0 2 (5.0%)
    1 38 (95%)
cad
    0 26 (65%)
    1 14 (35%)
cirrhosis
    0 38 (95%)
    1 2 (5.0%)
ace_arb
    0 8 (20%)
    1 32 (80%)
diu
    0 11 (28%)
    1 29 (73%)
ppi
    0 9 (23%)
    1 31 (78%)
steroids
    0 10 (25%)
    1 30 (75%)
smoking
    0 15 (38%)
    1 25 (63%)
statins
    0 2 (5.0%)
    1 38 (95%)
ICI_Class
    PD1 26 (65%)
    Combination 2 (5.0%)
    CTLA4 5 (13%)
    PDL1 7 (18%)
nephrotoxic_chemo
    0 30 (75%)
    1 10 (25%)
pre_CRE_180days 1.02 (0.78, 1.24)
pre_HGB_180days 12.55 (10.95, 13.95)
pre_ALB_180days 4.10 (3.90, 4.30)
eGFR_CRE_baseline 79 (59, 95)
1 Median (Q1, Q3); n (%)

9year

Characteristic N = 171
age_ici 67 (57, 74)
male
    0 6 (35%)
    1 11 (65%)
Race
    Asian 0 (0%)
    Black 0 (0%)
    Other/Unknown 0 (0%)
    White 17 (100%)
Ethnic_Group
    Hispanic 0 (0%)
    Non_hispanic 16 (94%)
    Other 1 (5.9%)
ckd_incidence_9year
    0 12 (71%)
    1 5 (29%)
ckd_progression_9year
    0 15 (88%)
    1 2 (12%)
eskd_composite_9year
    0 17 (100%)
    1 0 (0%)
ckd_composite_9year 7 (41%)
ckd_stage_1year
    1 4 (24%)
    2 10 (59%)
    3 3 (18%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_2year
    1 3 (18%)
    2 10 (59%)
    3 4 (24%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_3year
    1 4 (24%)
    2 9 (53%)
    3 4 (24%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_4year
    1 7 (41%)
    2 5 (29%)
    3 5 (29%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_5year
    1 4 (24%)
    2 8 (47%)
    3 5 (29%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_6year
    1 4 (24%)
    2 7 (41%)
    3 6 (35%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_7year
    1 6 (35%)
    2 5 (29%)
    3 6 (35%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_8year
    1 5 (29%)
    2 6 (35%)
    3 5 (29%)
    4 1 (5.9%)
    5 0 (0%)
ckd_stage_9year
    1 7 (41%)
    2 3 (18%)
    3 7 (41%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_baseline
    1 4 (24%)
    2 9 (53%)
    3 4 (24%)
    4 0 (0%)
    5 0 (0%)
aki
    0 8 (47%)
    1 9 (53%)
dm
    1 17 (100%)
htn
    0 0 (0%)
    1 17 (100%)
cad
    0 12 (71%)
    1 5 (29%)
cirrhosis
    0 17 (100%)
    1 0 (0%)
ace_arb
    0 4 (24%)
    1 13 (76%)
diu
    0 4 (24%)
    1 13 (76%)
ppi
    0 2 (12%)
    1 15 (88%)
steroids
    0 3 (18%)
    1 14 (82%)
smoking
    0 5 (29%)
    1 12 (71%)
statins
    0 0 (0%)
    1 17 (100%)
ICI_Class
    PD1 9 (53%)
    Combination 0 (0%)
    CTLA4 4 (24%)
    PDL1 4 (24%)
nephrotoxic_chemo
    0 11 (65%)
    1 6 (35%)
pre_CRE_180days 1.02 (0.83, 1.09)
pre_HGB_180days 12.60 (11.70, 14.40)
pre_ALB_180days
    3.5 1 (5.9%)
    3.9 1 (5.9%)
    4 2 (12%)
    4.1 2 (12%)
    4.2 5 (29%)
    4.3 3 (18%)
    4.4 2 (12%)
    4.8 1 (5.9%)
eGFR_CRE_baseline 77 (61, 88)
1 Median (Q1, Q3); n (%)

10year

Characteristic N = 61
age_ici
    60 1 (17%)
    67 1 (17%)
    71 1 (17%)
    72 1 (17%)
    74 1 (17%)
    75 1 (17%)
male
    0 2 (33%)
    1 4 (67%)
Race
    Asian 0 (0%)
    Black 0 (0%)
    Other/Unknown 0 (0%)
    White 6 (100%)
Ethnic_Group
    Hispanic 0 (0%)
    Non_hispanic 6 (100%)
    Other 0 (0%)
ckd_incidence_10year
    0 3 (50%)
    1 3 (50%)
ckd_progression_10year
    0 5 (83%)
    1 1 (17%)
eskd_composite_10year
    0 5 (83%)
    1 1 (17%)
ckd_composite_10year 4 (67%)
ckd_stage_1year
    1 1 (17%)
    2 3 (50%)
    3 2 (33%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_2year
    1 1 (17%)
    2 2 (33%)
    3 3 (50%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_3year
    1 1 (17%)
    2 2 (33%)
    3 3 (50%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_4year
    1 1 (17%)
    2 2 (33%)
    3 3 (50%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_5year
    1 1 (17%)
    2 2 (33%)
    3 3 (50%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_6year
    1 1 (17%)
    2 2 (33%)
    3 3 (50%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_7year
    1 0 (0%)
    2 2 (33%)
    3 4 (67%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_8year
    1 1 (17%)
    2 1 (17%)
    3 3 (50%)
    4 1 (17%)
    5 0 (0%)
ckd_stage_9year
    1 1 (17%)
    2 0 (0%)
    3 5 (83%)
    4 0 (0%)
    5 0 (0%)
ckd_stage_10year
    1 0 (0%)
    2 1 (17%)
    3 3 (50%)
    4 2 (33%)
    5 0 (0%)
ckd_stage_baseline
    1 1 (17%)
    2 3 (50%)
    3 2 (33%)
    4 0 (0%)
    5 0 (0%)
aki
    0 3 (50%)
    1 3 (50%)
dm
    1 6 (100%)
htn
    0 0 (0%)
    1 6 (100%)
cad
    0 4 (67%)
    1 2 (33%)
cirrhosis
    0 6 (100%)
    1 0 (0%)
ace_arb
    0 0 (0%)
    1 6 (100%)
diu
    0 1 (17%)
    1 5 (83%)
ppi
    0 0 (0%)
    1 6 (100%)
steroids
    0 1 (17%)
    1 5 (83%)
smoking
    0 0 (0%)
    1 6 (100%)
statins
    0 0 (0%)
    1 6 (100%)
ICI_Class
    PD1 3 (50%)
    Combination 0 (0%)
    CTLA4 3 (50%)
    PDL1 0 (0%)
nephrotoxic_chemo
    0 4 (67%)
    1 2 (33%)
pre_CRE_180days
    0.66 1 (17%)
    0.81 1 (17%)
    1.01 1 (17%)
    1.02 1 (17%)
    1.3 1 (17%)
    1.52 1 (17%)
pre_HGB_180days
    11.3 1 (17%)
    12.2 1 (17%)
    13.3 1 (17%)
    13.9 1 (17%)
    14.6 1 (17%)
    14.8 1 (17%)
pre_ALB_180days
    4.1 1 (17%)
    4.2 1 (17%)
    4.3 2 (33%)
    4.4 1 (17%)
    4.8 1 (17%)
eGFR_CRE_baseline
    47.0718538399253 1 (17%)
    59.186554146736 1 (17%)
    61.3166133202947 1 (17%)
    80.4651484382125 1 (17%)
    82.827699890859 1 (17%)
    104.256040676399 1 (17%)
1 n (%)

CIF survival all Event number : death + ckd composite

ckd_stage vs ckd_composite_1year

0
(N=1181)		 1
(N=80)		 Overall
(N=1261)
ckd_stage_baseline
1 424 (35.9%) 9 (11.3%) 433 (34.3%)
2 465 (39.4%) 51 (63.8%) 516 (40.9%)
3 274 (23.2%) 17 (21.3%) 291 (23.1%)
4 18 (1.5%) 2 (2.5%) 20 (1.6%)
5 0 (0%) 1 (1.3%) 1 (0.1%)
factor(ckd_stage_1year)
1 393 (33.3%) 0 (0%) 393 (31.2%)
2 495 (41.9%) 9 (11.3%) 504 (40.0%)
3 272 (23.0%) 57 (71.3%) 329 (26.1%)
4 21 (1.8%) 11 (13.8%) 32 (2.5%)
5 0 (0%) 3 (3.8%) 3 (0.2%)

ckd_stage vs ckd_composite_2year

0
(N=665)		 1
(N=98)		 Overall
(N=763)
ckd_stage_baseline
1 249 (37.4%) 13 (13.3%) 262 (34.3%)
2 256 (38.5%) 59 (60.2%) 315 (41.3%)
3 149 (22.4%) 22 (22.4%) 171 (22.4%)
4 11 (1.7%) 3 (3.1%) 14 (1.8%)
5 0 (0%) 1 (1.0%) 1 (0.1%)
factor(ckd_stage_2year)
1 220 (33.1%) 0 (0%) 220 (28.8%)
2 302 (45.4%) 17 (17.3%) 319 (41.8%)
3 127 (19.1%) 68 (69.4%) 195 (25.6%)
4 16 (2.4%) 9 (9.2%) 25 (3.3%)
5 0 (0%) 4 (4.1%) 4 (0.5%)

ckd_stage vs ckd_composite_3year

0
(N=365)		 1
(N=81)		 Overall
(N=446)
ckd_stage_baseline
1 151 (41.4%) 14 (17.3%) 165 (37.0%)
2 130 (35.6%) 46 (56.8%) 176 (39.5%)
3 80 (21.9%) 19 (23.5%) 99 (22.2%)
4 4 (1.1%) 2 (2.5%) 6 (1.3%)
5 0 (0%) 0 (0%) 0 (0%)
factor(ckd_stage_3year)
1 124 (34.0%) 2 (2.5%) 126 (28.3%)
2 160 (43.8%) 22 (27.2%) 182 (40.8%)
3 76 (20.8%) 48 (59.3%) 124 (27.8%)
4 5 (1.4%) 7 (8.6%) 12 (2.7%)
5 0 (0%) 2 (2.5%) 2 (0.4%)

ckd_stage vs ckd_composite_4year

0
(N=218)		 1
(N=63)		 Overall
(N=281)
ckd_stage_baseline
1 85 (39.0%) 11 (17.5%) 96 (34.2%)
2 83 (38.1%) 33 (52.4%) 116 (41.3%)
3 47 (21.6%) 18 (28.6%) 65 (23.1%)
4 3 (1.4%) 1 (1.6%) 4 (1.4%)
5 0 (0%) 0 (0%) 0 (0%)
factor(ckd_stage_4year)
1 77 (35.3%) 1 (1.6%) 78 (27.8%)
2 94 (43.1%) 21 (33.3%) 115 (40.9%)
3 45 (20.6%) 37 (58.7%) 82 (29.2%)
4 2 (0.9%) 3 (4.8%) 5 (1.8%)
5 0 (0%) 1 (1.6%) 1 (0.4%)

ckd_stage vs ckd_composite_5year

0
(N=129)		 1
(N=48)		 Overall
(N=177)
ckd_stage_baseline
1 57 (44.2%) 3 (6.3%) 60 (33.9%)
2 49 (38.0%) 27 (56.3%) 76 (42.9%)
3 21 (16.3%) 17 (35.4%) 38 (21.5%)
4 2 (1.6%) 1 (2.1%) 3 (1.7%)
5 0 (0%) 0 (0%) 0 (0%)
factor(ckd_stage_5year)
1 40 (31.0%) 4 (8.3%) 44 (24.9%)
2 74 (57.4%) 13 (27.1%) 87 (49.2%)
3 12 (9.3%) 28 (58.3%) 40 (22.6%)
4 3 (2.3%) 2 (4.2%) 5 (2.8%)
5 0 (0%) 1 (2.1%) 1 (0.6%)

Table 5 year aki

Overall
(N=48)
aki
0 17 (35.4%)
1 31 (64.6%)
as.factor(aki_before_ckd)
0 9 (18.8%)
1 22 (45.8%)
Missing 17 (35.4%)
Overall
(N=2653)
aki
0 1651 (62.2%)
1 1002 (37.8%)
as.factor(aki_before_ckd)
0 46 (1.7%)
1 104 (3.9%)
Missing 2503 (94.3%)
ckd_composite
0 2420 (91.2%)
1 233 (8.8%)

Table ckd_composite==1 columns:aki_before_ckd

Characteristic N = 2071
age_ici 71 (64, 77)
male
    0 93 (45%)
    1 114 (55%)
Race
    Asian 3 (1.4%)
    Black 13 (6.3%)
    Other/Unknown 9 (4.3%)
    White 182 (88%)
Ethnic_Group
    Hispanic 8 (3.9%)
    Non_hispanic 186 (90%)
    Other 13 (6.3%)
ckd_incidence_1year
    0 148 (71%)
    1 59 (29%)
ckd_progression_1year
    0 190 (92%)
    1 17 (8.2%)
eskd_composite_1year
    0 199 (96%)
    1 8 (3.9%)
ckd_composite_1year
    0 127 (61%)
    1 80 (39%)
ckd_stage_1year
    1 14 (6.8%)
    2 66 (32%)
    3 108 (52%)
    4 16 (7.7%)
    5 3 (1.4%)
ckd_stage_baseline
    1 32 (15%)
    2 115 (56%)
    3 52 (25%)
    4 7 (3.4%)
    5 1 (0.5%)
aki
    0 76 (37%)
    1 131 (63%)
dm
    1 207 (100%)
htn
    0 19 (9.2%)
    1 188 (91%)
cad
    0 98 (47%)
    1 109 (53%)
cirrhosis
    0 201 (97%)
    1 6 (2.9%)
ace_arb
    0 42 (20%)
    1 165 (80%)
diu
    0 42 (20%)
    1 165 (80%)
ppi
    0 34 (16%)
    1 173 (84%)
steroids
    0 40 (19%)
    1 167 (81%)
smoking
    0 77 (37%)
    1 130 (63%)
statins
    0 25 (12%)
    1 182 (88%)
ICI_Class
    PD1 136 (66%)
    Combination 31 (15%)
    CTLA4 6 (2.9%)
    PDL1 34 (16%)
nephrotoxic_chemo
    0 114 (55%)
    1 93 (45%)
pre_CRE_180days 1.01 (0.82, 1.23)
pre_HGB_180days 11.90 (10.80, 13.10)
    Missing 1
pre_ALB_180days 4.00 (3.70, 4.20)
    Missing 3
eGFR_CRE_baseline 74 (55, 83)
1 Median (Q1, Q3); n (%)
Characteristic 0
N = 1291		 1
N = 1041
age_ici 71 (66, 78) 71 (63, 78)
male

    0 58 (45%) 48 (46%)
    1 71 (55%) 56 (54%)
Race

    Asian 2 (1.6%) 1 (1.0%)
    Black 7 (5.4%) 7 (6.7%)
    Other/Unknown 5 (3.9%) 5 (4.8%)
    White 115 (89%) 91 (88%)
Ethnic_Group

    Hispanic 6 (4.7%) 5 (4.8%)
    Non_hispanic 117 (91%) 92 (88%)
    Other 6 (4.7%) 7 (6.7%)
ckd_composite

    0 0 (0%) 0 (0%)
    1 129 (100%) 104 (100%)
ckd_incidence

    0 31 (24%) 48 (46%)
    1 98 (76%) 56 (54%)
ckd_progression

    0 108 (84%) 69 (66%)
    1 21 (16%) 35 (34%)
ckd_stage_baseline

    1 12 (9.3%) 21 (20%)
    2 88 (68%) 40 (38%)
    3 22 (17%) 38 (37%)
    4 5 (3.9%) 4 (3.8%)
    5 2 (1.6%) 1 (1.0%)
aki

    0 83 (64%) 0 (0%)
    1 46 (36%) 104 (100%)
dm

    1 129 (100%) 104 (100%)
htn

    0 16 (12%) 6 (5.8%)
    1 113 (88%) 98 (94%)
cad

    0 70 (54%) 44 (42%)
    1 59 (46%) 60 (58%)
cirrhosis

    0 126 (98%) 99 (95%)
    1 3 (2.3%) 5 (4.8%)
ace_arb

    0 32 (25%) 14 (13%)
    1 97 (75%) 90 (87%)
diu

    0 36 (28%) 12 (12%)
    1 93 (72%) 92 (88%)
ppi

    0 25 (19%) 16 (15%)
    1 104 (81%) 88 (85%)
steroids

    0 25 (19%) 18 (17%)
    1 104 (81%) 86 (83%)
smoking

    0 53 (41%) 33 (32%)
    1 76 (59%) 71 (68%)
statins

    0 20 (16%) 7 (6.7%)
    1 109 (84%) 97 (93%)
ICI_Class

    PD1 90 (70%) 65 (63%)
    Combination 18 (14%) 15 (14%)
    CTLA4 3 (2.3%) 3 (2.9%)
    PDL1 18 (14%) 21 (20%)
nephrotoxic_chemo

    0 67 (52%) 59 (57%)
    1 62 (48%) 45 (43%)
pre_CRE_180days 0.99 (0.81, 1.20) 1.05 (0.83, 1.39)
pre_HGB_180days 11.80 (10.45, 13.10) 11.80 (10.70, 12.75)
    Missing 1 0
pre_ALB_180days 4.00 (3.60, 4.20) 3.90 (3.70, 4.15)
    Missing 3 0
eGFR_CRE_baseline 75 (63, 82) 68 (50, 84)
1 Median (Q1, Q3); n (%)

logistic regression outcome: ckd_composite_5year

Characteristic N OR1 95% CI1 p-value
year_10 177 1.50 1.07, 2.16 0.024
male 177


    0
— —
    1
0.49 0.25, 0.96 0.039
Race 177


    Asian
— —
    Black
3,838,542 0.00,
0.986
    Other/Unknown
2,559,028 0.00,
0.986
    White
2,074,887 0.00,
0.986
htn 177


    0
— —
    1
2.28 0.72, 10.1 0.206
cad 177


    0
— —
    1
3.12 1.58, 6.25 0.001
cirrhosis 177


    0
— —
    1
0.66 0.03, 4.64 0.718
ace_arb 177


    0
— —
    1
2.03 0.83, 5.73 0.144
diu 177


    0
— —
    1
3.59 1.43, 11.0 0.012
ppi 177


    0
— —
    1
1.32 0.57, 3.34 0.528
steroids 177


    0
— —
    1
0.73 0.33, 1.69 0.446
smoking 177


    0
— —
    1
1.19 0.60, 2.41 0.617
statins 177


    0
— —
    1
1.90 0.67, 6.83 0.267
nephrotoxic_chemo 177


    0
— —
    1
0.92 0.46, 1.80 0.805
Bevacizumab 177


    0
— —
    1
2.84 0.65, 12.5 0.152
Cisplatin 177


    0
— —
    1
0.55 0.12, 1.78 0.362
Carboplatin 177


    0
— —
    1
1.22 0.58, 2.49 0.589
Pemetrexed 177


    0
— —
    1
1.30 0.47, 3.31 0.597
Gemcitabine 177


    0
— —
    1
1.66 0.59, 4.43 0.317
Cetuximab 177


    0
— —
    1
0.00
0.989
Trastuzumab 177


    0
— —
    1
0.00
0.989
eGFR_CRE_baseline_decrease_10 177 1.42 1.20, 1.70 <0.001
ICI_Class 177


    PD1
— —
    Combination
1.15 0.30, 3.71 0.823
    CTLA4
0.82 0.12, 3.61 0.812
    PDL1
1.44 0.59, 3.34 0.408
cancer_group 177


    cutaneous / melanoma
— —
    gi
3.73 0.77, 18.2 0.093
    gu
2.03 0.77, 5.43 0.151
    gyn
2.80 0.49, 14.6 0.219
    other
1.19 0.41, 3.35 0.739
    thoracic
1.13 0.42, 3.00 0.806
1 OR = Odds Ratio, CI = Confidence Interval

Multivariate logistic regression outcome: ckd_composite_5year

Characteristic N OR1 95% CI1 p-value
year_10 177 1.18 0.78, 1.79 0.426
male 177


    0
— —
    1
0.24 0.10, 0.55 <0.001
htn 177


    0
— —
    1
0.96 0.25, 4.81 0.960
cad 177


    0
— —
    1
3.29 1.45, 7.77 0.005
ppi 177


    0
— —
    1
1.02 0.40, 2.77 0.974
smoking 177


    0
— —
    1
1.08 0.47, 2.48 0.861
eGFR_CRE_baseline_decrease_10 177 1.46 1.20, 1.80 <0.001
nephrotoxic_chemo 177


    0
— —
    1
0.75 0.33, 1.65 0.482
1 OR = Odds Ratio, CI = Confidence Interval

Multivariate logistic regression outcome: ckd_composite_5year

Characteristic N OR1 95% CI1 p-value
year_10 177 1.24 0.81, 1.93 0.324
male 177


    0
— —
    1
0.23 0.09, 0.53 <0.001
htn 177


    0
— —
    1
0.84 0.21, 4.41 0.824
cad 177


    0
— —
    1
3.63 1.53, 9.07 0.004
ppi 177


    0
— —
    1
0.84 0.32, 2.36 0.734
smoking 177


    0
— —
    1
0.94 0.39, 2.22 0.880
eGFR_CRE_baseline_decrease_10 177 1.48 1.21, 1.86 <0.001
Bevacizumab 177


    0
— —
    1
2.17 0.40, 11.7 0.355
Cisplatin 177


    0
— —
    1
0.24 0.04, 1.18 0.102
Carboplatin 177


    0
— —
    1
0.75 0.24, 2.18 0.606
Pemetrexed 177


    0
— —
    1
2.68 0.64, 11.6 0.177
Gemcitabine 177


    0
— —
    1
1.50 0.37, 6.10 0.565
Cetuximab 177


    0
— —
    1
0.00
0.992
Trastuzumab 177


    0
— —
    1
0.00
0.993
1 OR = Odds Ratio, CI = Confidence Interval

Multivariate logistic regression outcome: ckd_composite_5year

Characteristic N OR1 95% CI1 p-value
year_10 177 1.17 0.78, 1.78 0.448
male 177


    0
— —
    1
0.25 0.10, 0.56 0.001
htn 177


    0
— —
    1
0.94 0.24, 4.67 0.931
cad 177


    0
— —
    1
3.28 1.44, 7.76 0.005
ppi 177


    0
— —
    1
1.00 0.39, 2.74 0.995
smoking 177


    0
— —
    1
1.04 0.45, 2.42 0.922
eGFR_CRE_baseline_decrease_10 177 1.46 1.20, 1.80 <0.001
nephrotoxic_chemo 177


    0
— —
    1
0.76 0.33, 1.67 0.495
statins 177


    0
— —
    1
1.41 0.43, 5.63 0.589
1 OR = Odds Ratio, CI = Confidence Interval

Fine & Grey model for all

Characteristic N HR1 95% CI1 p-value
year_10 2,653 1.14 1.01, 1.27 0.029
male 2,653


    0
— —
    1
0.70 0.54, 0.91 0.007
Race 2,653


    Asian
— —
    Black
2.95 0.84, 10.3 0.091
    Other/Unknown
2.31 0.63, 8.44 0.210
    White
3.21 1.02, 10.1 0.047
htn 2,653


    0
— —
    1
1.08 0.70, 1.68 0.730
cad 2,653


    0
— —
    1
1.28 0.99, 1.65 0.060
cirrhosis 2,653


    0
— —
    1
0.62 0.31, 1.24 0.180
ace_arb 2,653


    0
— —
    1
1.53 1.11, 2.11 0.010
diu 2,653


    0
— —
    1
1.49 1.08, 2.04 0.014
ppi 2,653


    0
— —
    1
1.04 0.75, 1.46 0.800
steroids 2,653


    0
— —
    1
0.74 0.53, 1.03 0.072
smoking 2,653


    0
— —
    1
1.02 0.78, 1.34 0.860
statins 2,653


    0
— —
    1
2.07 1.39, 3.09 <0.001
nephrotoxic_chemo 2,653


    0
— —
    1
0.75 0.58, 0.97 0.028
Bevacizumab 2,653


    0
— —
    1
0.71 0.40, 1.25 0.230
Cisplatin 2,653


    0
— —
    1
0.68 0.44, 1.05 0.082
Carboplatin 2,653


    0
— —
    1
0.97 0.74, 1.28 0.850
Pemetrexed 2,653


    0
— —
    1
1.45 1.04, 2.03 0.028
Gemcitabine 2,653


    0
— —
    1
0.84 0.56, 1.27 0.420
Cetuximab 2,653


    0
— —
    1
0.29 0.07, 1.17 0.082
Trastuzumab 2,653


    0
— —
    1
0.80 0.29, 2.17 0.660
eGFR_CRE_baseline_decrease_10 2,653 1.18 1.12, 1.24 <0.001
ICI_Class 2,653


    PD1
— —
    Combination
1.33 0.92, 1.94 0.130
    CTLA4
0.66 0.30, 1.45 0.300
    PDL1
1.03 0.72, 1.46 0.880
cancer_group 2,653


    cutaneous / melanoma
— —
    gi
0.63 0.40, 0.99 0.046
    gu
1.28 0.85, 1.94 0.240
    gyn
0.83 0.42, 1.67 0.610
    other
0.46 0.28, 0.76 0.003
    thoracic
0.80 0.54, 1.19 0.270
1 HR = Hazard Ratio, CI = Confidence Interval

Fine & Grey model for all multivaiate model

Characteristic N HR1 95% CI1 p-value
year_10 2,653 0.93 0.81, 1.07 0.3
male 2,653


    0
— —
    1
0.67 0.52, 0.88 0.003
htn 2,653


    0
— —
    1
0.91 0.57, 1.46 0.7
cad 2,653


    0
— —
    1
1.25 0.95, 1.65 0.11
ppi 2,653


    0
— —
    1
1.03 0.73, 1.46 0.9
smoking 2,653


    0
— —
    1
0.99 0.75, 1.31 >0.9
eGFR_CRE_baseline_decrease_10 2,653 1.19 1.12, 1.25 <0.001
Bevacizumab 2,653


    0
— —
    1
0.80 0.45, 1.43 0.5
Cisplatin 2,653


    0
— —
    1
0.69 0.45, 1.06 0.088
Carboplatin 2,653


    0
— —
    1
0.83 0.61, 1.13 0.2
Pemetrexed 2,653


    0
— —
    1
1.73 1.18, 2.53 0.005
Gemcitabine 2,653


    0
— —
    1
0.91 0.61, 1.36 0.6
Cetuximab 2,653


    0
— —
    1
0.46 0.11, 1.89 0.3
Trastuzumab 2,653


    0
— —
    1
0.87 0.31, 2.41 0.8
1 HR = Hazard Ratio, CI = Confidence Interval

Fine & Grey model for all multivaiate model

Characteristic N HR1 95% CI1 p-value
year_10 2,653 0.95 0.84, 1.09 0.5
male 2,653


    0
— —
    1
0.66 0.51, 0.86 0.002
htn 2,653


    0
— —
    1
0.90 0.57, 1.44 0.7
cad 2,653


    0
— —
    1
1.24 0.95, 1.63 0.12
ppi 2,653


    0
— —
    1
1.05 0.74, 1.49 0.8
smoking 2,653


    0
— —
    1
1.06 0.81, 1.40 0.7
eGFR_CRE_baseline_decrease_10 2,653 1.17 1.11, 1.24 <0.001
nephrotoxic_chemo 2,653


    0
— —
    1
0.77 0.59, 1.00 0.046
1 HR = Hazard Ratio, CI = Confidence Interval

Fine & Grey model for all multivaiate model

Characteristic N HR1 95% CI1 p-value
year_10 2,653 0.93 0.81, 1.07 0.3
male 2,653


    0
— —
    1
0.63 0.49, 0.83 <0.001
htn 2,653


    0
— —
    1
0.79 0.50, 1.26 0.3
cad 2,653


    0
— —
    1
1.20 0.91, 1.58 0.2
ppi 2,653


    0
— —
    1
1.00 0.70, 1.41 >0.9
smoking 2,653


    0
— —
    1
1.05 0.80, 1.38 0.7
eGFR_CRE_baseline_decrease_10 2,653 1.17 1.10, 1.23 <0.001
nephrotoxic_chemo 2,653


    0
— —
    1
0.75 0.57, 0.97 0.030
statins 2,653


    0
— —
    1
1.99 1.32, 3.02 0.001
1 HR = Hazard Ratio, CI = Confidence Interval